Trial Profile
A phase 1 study of lopinavir/ritonavir on the pharmacokinetics of selexipag and its active metabolite ACT-333679 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 05 Dec 2015 New trial record